written by reader PTN News Release: AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder

By 23Scadoo, January 9, 2017